Ranibizumab w leczeniu cukrzycowego obrzęku plamki
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2019
Słowa kluczowe:
cukrzyca, retinopatia cukrzycowa, obrzęk plamki, leczenie anty-VEGF
##plugins.themes.bootstrap3.article.main##
Abstrakt
Cukrzyca jest chorobą stanowiącą duży problem społeczny. Badania epidemiologiczne dotyczące zapadalności na cukrzycę typu 1 i 2 na świecie wykazują ciągły wzrost liczby zachorowań. Wraz ze wzrostem czasu trwania cukrzycy wzrasta prawdopodobieństwo znacznych zmian naczyniowych siatkówki i rozwoju obrzęku plamki. Zastosowanie ranibizumabu w iniekcji doszklistkowej zrewolucjonizowało leczenie powikłań ocznych cukrzycy. Lek ten stosowany jest w ramach leczenia pierwszego rzutu w przypadku klinicznie znamiennego obrzęku plamki z zajęciem dołka i pogorszeniem ostrości wzroku. W licznych badaniach wykazano większą skuteczność jego leczenia ranibizumabem – zarówno w monoteraii, jak i w skojarzeniu z laseroterapią – w porównaniu z laseroterapią, która do niedawna jeszcze była złotym standardem leczenia.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Bryl A, Mrugacz M. Ranibizumab w leczeniu cukrzycowego obrzęku plamki. Ophthatherapy [Internet]. 30 czerwiec 2019 [cytowane 3 lipiec 2024];6(2):105-9. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/939
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Beyloe JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001; 24(11): 1936-40.
2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and complications: estimates and projections to the year 2010. Diabet Med. 1997; 14(5): 1-5.
3. Chojnowski P, Wasyluk J, Grabska-Liberek I. Cukrzyca – epidemiologia i patogeneza. Postępy Nauk Medycznych. 2009; 6: 420-8.
4. Foulds WS, MacCuish ATB. Diabetic retinopathy in the west of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening programme. Health Bulletin. 1983; 41(6): 318-26.
5. Prevention of blindness from diabetes mellitus. Report of WHO consultation in Geneva, Switzerland, 9-11 November 2005.
6. Wild S, Roglic G, Green A et al. Global Prevalance of Diabetes. Estimates for the year 2000 and projections for 2030. Diab Care. 2004; 27(5): 1047-53.
7. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract. 2012; 98: 524-5. https://doi.org/ 10.1016/j.diabres.2012.11.006.
8. Resnikoff S, Pascolini D, Etya‘ale D et al. Global Data on Visual impairment in the year 2002. Bulletin of the World Health Organization. 2004; 82: 844-51.
9. Kempen JH, O’Colmain BJ, Leske MC et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004; 122(4): 552-63.
10. Roy MS, Klein R, O‘Colmain BJ et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004; 122: 546-51.
11. Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diab Care. 2012; 35: 556-64.
12. Shin ES, Sorenson CM, Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res. 2014; 9(3): 362-73. https://doi.org/ 10.4103/2008-322x.143378.
13. Regillo CD. Retina and vitreous. Basic and Clinical Science Course. Section 12, 2005-2006. American Academy of Ophthalmology.
14. Arden GB, Sidman RL, Arap W et al. Spare the rod and spoil the eye. Br J Ophthalmol. 2005; 89: 764-9.
15. Simó R, Hernández C. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol. 2012; 96(10): 1285-90.
16. Marczak M. Zastosowanie ranibizumabu w leczeniu cukrzycowego obrzęku plamki w materiale własnym. OphthaTherapy. 2014; 1(3): 165-9.
17. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6): 998-1003.
18. Kur J, Newman EA, Chang-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina choroid in health diseases. Prog Retin Eye Res. 2012; 31(5): 377-406.
19. Bandello F, Lattanzio R, Zucchiatti I et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013; 50: 1-20.
20. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7: 41-53.
21. Klein R, Klein B, Moss S et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macula edema. Ophthalmology. 1995; 102: 7-16.
22. Kański J, Milewski SA. Choroby plamki. WM Górnicki, Wrocław 2003.
23. Aiello LP, Avery LR, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-7.
24. Browning DJ, Glassman AR, Aiello LP et al. Diabetic Retinopathy Clinical Research Network: Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008; 115(8): 1366-71.
25. Kubicka-Trząska A. Doszklistkowe iniekcje ranibizumabu w leczeniu cukrzycowego obrzęku plamki. Klin Okulist. 2010: 10-2.
26. Nguyen QD, Shah SM, Heier JS et al. Primary end point (six months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study. Ophthalmology. 2009; 116: 2175-81.
27. Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with cente-rinvolving clinically significant diabetic macular edema. Ophthalmology. 2006; 113(10): 1706-12.
28. Vellanki S, Ferrigno A, Alanis Y et al. High glucose and glucose deprivation modulate müller cell viability and VEGF Secretion. Int J Ophthalmol Eye Sci. 2016; 4: 178-83.
29. Rejdak R, Ozimek M, Chorągiewicz T et al. Współczesne możliwości leczenia cukrzycowego obrzęku plamki – wyniki własne. Ophthalmol J. 2017; 2(1): 1-7.
30. Novartis – monografia produktu leczniczego Lucentis.
31. Teper S. Nowe trendy w leczeniu cukrzycowego obrzęku plamki. Przegląd Okulistyczny. 2011; 2(40): 9.
32. Mitchell P, Bandello F, Schmidt-Erfurth U et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615-25.
33. Szilard K. Moving Beyond Laser in treatment DME, BRVO. Retina Today. 2012: 48-50.
34. Brown DM, Nguyen QD, Marcus DM; RIDE and RISE Research Group. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema. The 36-Month Results from Two Phase III Trials: RISE and RIDE. Ophthalmology. 2013. https://doi.org/ 2013.02.034.
35. Do DV, Nguyen QD, Boyer D et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8): 1658-65.
36. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116(6): 1142-50.
37. Elman M, Ayala A, Bressler N et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus eferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122: 375-81.
38. Mrugacz M, Krajewska M, Bryl A et al. Evaluate the effectiveness of laser therapy in the treatment of diabetic maculopathy. Pol Merk Lek. 2013; 34(204): 351-4.
2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and complications: estimates and projections to the year 2010. Diabet Med. 1997; 14(5): 1-5.
3. Chojnowski P, Wasyluk J, Grabska-Liberek I. Cukrzyca – epidemiologia i patogeneza. Postępy Nauk Medycznych. 2009; 6: 420-8.
4. Foulds WS, MacCuish ATB. Diabetic retinopathy in the west of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening programme. Health Bulletin. 1983; 41(6): 318-26.
5. Prevention of blindness from diabetes mellitus. Report of WHO consultation in Geneva, Switzerland, 9-11 November 2005.
6. Wild S, Roglic G, Green A et al. Global Prevalance of Diabetes. Estimates for the year 2000 and projections for 2030. Diab Care. 2004; 27(5): 1047-53.
7. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract. 2012; 98: 524-5. https://doi.org/ 10.1016/j.diabres.2012.11.006.
8. Resnikoff S, Pascolini D, Etya‘ale D et al. Global Data on Visual impairment in the year 2002. Bulletin of the World Health Organization. 2004; 82: 844-51.
9. Kempen JH, O’Colmain BJ, Leske MC et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004; 122(4): 552-63.
10. Roy MS, Klein R, O‘Colmain BJ et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004; 122: 546-51.
11. Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diab Care. 2012; 35: 556-64.
12. Shin ES, Sorenson CM, Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res. 2014; 9(3): 362-73. https://doi.org/ 10.4103/2008-322x.143378.
13. Regillo CD. Retina and vitreous. Basic and Clinical Science Course. Section 12, 2005-2006. American Academy of Ophthalmology.
14. Arden GB, Sidman RL, Arap W et al. Spare the rod and spoil the eye. Br J Ophthalmol. 2005; 89: 764-9.
15. Simó R, Hernández C. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol. 2012; 96(10): 1285-90.
16. Marczak M. Zastosowanie ranibizumabu w leczeniu cukrzycowego obrzęku plamki w materiale własnym. OphthaTherapy. 2014; 1(3): 165-9.
17. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6): 998-1003.
18. Kur J, Newman EA, Chang-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina choroid in health diseases. Prog Retin Eye Res. 2012; 31(5): 377-406.
19. Bandello F, Lattanzio R, Zucchiatti I et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013; 50: 1-20.
20. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7: 41-53.
21. Klein R, Klein B, Moss S et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macula edema. Ophthalmology. 1995; 102: 7-16.
22. Kański J, Milewski SA. Choroby plamki. WM Górnicki, Wrocław 2003.
23. Aiello LP, Avery LR, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-7.
24. Browning DJ, Glassman AR, Aiello LP et al. Diabetic Retinopathy Clinical Research Network: Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008; 115(8): 1366-71.
25. Kubicka-Trząska A. Doszklistkowe iniekcje ranibizumabu w leczeniu cukrzycowego obrzęku plamki. Klin Okulist. 2010: 10-2.
26. Nguyen QD, Shah SM, Heier JS et al. Primary end point (six months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study. Ophthalmology. 2009; 116: 2175-81.
27. Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with cente-rinvolving clinically significant diabetic macular edema. Ophthalmology. 2006; 113(10): 1706-12.
28. Vellanki S, Ferrigno A, Alanis Y et al. High glucose and glucose deprivation modulate müller cell viability and VEGF Secretion. Int J Ophthalmol Eye Sci. 2016; 4: 178-83.
29. Rejdak R, Ozimek M, Chorągiewicz T et al. Współczesne możliwości leczenia cukrzycowego obrzęku plamki – wyniki własne. Ophthalmol J. 2017; 2(1): 1-7.
30. Novartis – monografia produktu leczniczego Lucentis.
31. Teper S. Nowe trendy w leczeniu cukrzycowego obrzęku plamki. Przegląd Okulistyczny. 2011; 2(40): 9.
32. Mitchell P, Bandello F, Schmidt-Erfurth U et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615-25.
33. Szilard K. Moving Beyond Laser in treatment DME, BRVO. Retina Today. 2012: 48-50.
34. Brown DM, Nguyen QD, Marcus DM; RIDE and RISE Research Group. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema. The 36-Month Results from Two Phase III Trials: RISE and RIDE. Ophthalmology. 2013. https://doi.org/ 2013.02.034.
35. Do DV, Nguyen QD, Boyer D et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8): 1658-65.
36. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116(6): 1142-50.
37. Elman M, Ayala A, Bressler N et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus eferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122: 375-81.
38. Mrugacz M, Krajewska M, Bryl A et al. Evaluate the effectiveness of laser therapy in the treatment of diabetic maculopathy. Pol Merk Lek. 2013; 34(204): 351-4.